Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β 3-Src Pathway

3 Oct 2013

Abstract excerpt

BACKGROUND: Several phase II/III trials of anti-insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibodies (mAbs) have shown limited efficacy. The mechanisms of resistance to IGF-1R mAb-based therapies and clinically applicable strategies for overcoming drug resistance are still undefined. METHODS: IGF-1R mAb cixutumumab efficacy, alone or in combination with Src inhibitors, was evaluated in 10 human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion Molecules Research
Share to Growth Hormone and Insulin-like Growth Factors
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24092920
DOI: 10.1093/jnci/djt263

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β 3-Src PathwayPMID 24092920Read ↗

Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancerSemantic proximity Read ↗

Mechanisms of resistance to ErbB-targeted cancer therapeutics.Semantic proximity Read ↗

Differential Mechanisms of Acquired Resistance to Insulin-like Growth Factor-I Receptor Antibody Therapy or to a Small-Molecule Inhibitor, BMS-754807, in a Human Rhabdomyosarcoma ModelSemantic proximity Read ↗

Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancerSemantic proximity Read ↗

Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapySemantic proximity Read ↗

High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507).Semantic proximity Read ↗

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.Semantic proximity Read ↗

The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 InhibitorsSemantic proximity Read ↗

Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonistsSemantic proximity Read ↗

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapySemantic proximity Read ↗

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.Semantic proximity Read ↗

TGFβ1/integrin β3 positive feedback loop contributes to acquired EGFR TKI resistance in EGFR-mutant lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.